• Antidepressant Effects of Rotigotine in Preclinical Depressi

  2026-07-04

  This study systematically evaluated rotigotine, a non-ergoline dopamine D2/D3 receptor agonist, for antidepressant activity across established rodent models. The findings suggest that rotigotine exerts dose-dependent antidepressant-like effects, expanding its potential beyond motor symptom management in Parkinson’s disease and providing a foundation for further translational research.

• Angiotensin II for Vascular Remodeling: Protocols & Innovati

  2026-07-03

  Unlock the potential of APExBIO's Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) for advanced cardiovascular and hypertension research. This in-depth guide outlines optimized workflows, troubleshooting insights, and leverages recent breakthroughs linking environmental exposure to vascular disease models.

• Melittin: Unlocking GPCR Signal Modulation in GBM Research

  2026-07-03

  This article explores the mechanistic and translational impact of Melittin, a bioactive peptide, in glioblastoma (GBM) research. By integrating recent insights into GPCR signaling, lipid metabolism, and cell death pathways, we provide strategic guidance for researchers seeking to harness Melittin’s unique dual action as a Gs protein inhibitor and Gi protein activator. The discussion bridges foundational biology with protocol optimization, workflow recommendations, and a forward-looking perspective on GBM therapeutic innovation.

• Rapid In Vivo Screening for PDA Chemotherapeutics Using Rgs1

  2026-07-02

  This study introduces a concerted cell and in vivo screening approach leveraging Rgs16::GFP as a biomarker for evaluating chemotherapeutic combinations in pancreatic ductal adenocarcinoma (PDA). The findings highlight the synergistic potential of histone deacetylase and BET bromodomain inhibition with gemcitabine, offering a robust framework for preclinical assessment of epigenetic therapies.

• Perphenazine: A Dopamine D2 Antagonist for Host-Pathogen Res

  2026-07-02

  Perphenazine, a multi-receptor dopamine D2 antagonist, is reshaping experimental workflows in both neuropharmacology and host-pathogen research. Its dual roles in inducing mitochondria-mediated cell death and enhancing macrophage antibacterial activity offer unique advantages for studies of schizophrenia, opioid tolerance, and antibiotic resistance.

• Strategic Hedgehog Pathway Activation: SAG in Translational

  2026-07-01

  Smoothened Agonist (SAG) is reshaping translational frameworks across developmental biology, neuroregeneration, and disease modeling. This thought-leadership article provides a mechanistic deep dive into Hedgehog pathway activation via the Smo receptor, evaluates recent evidence on developmental risks, and delivers practical protocol guidance for maximizing SAG’s translational impact. Drawing from peer-reviewed research and competitive analyses, we clarify how APExBIO’s SAG stands out as a trusted tool for robust, reproducible outcomes—and how emerging data on teratogenicity and sex-dependent effects should inform responsible, forward-thinking research design.

• KU-60019: ATM Kinase Inhibitor Workflows for Glioma Research

  2026-07-01

  KU-60019 stands out as a potent ATM kinase inhibitor, enabling researchers to dissect DNA damage response, radiosensitization, and metabolic adaptation in glioma models. This guide bridges bench protocols and the latest insights on metabolic vulnerabilities, highlighting solutions for real-world experimental challenges.

• Cediranib (AZD2171): Reliable VEGFR Inhibition in Cancer Res

  2026-06-30

  This article guides biomedical scientists through common challenges in cell viability and cancer assay workflows, demonstrating how Cediranib (AZD2171), SKU A1882, offers data-driven solutions for reproducibility and mechanistic clarity. Drawing from both product dossier parameters and contemporary in vitro evaluation literature, it highlights optimal use cases for this potent VEGFR tyrosine kinase inhibitor.

• Palmitic acid (Hexadecanoic Acid): Technical Guidance for Re

  2026-06-30

  Palmitic acid (SKU N2456) addresses the need for a high-purity, well-characterized saturated long-chain fatty acid for accurate in vitro modeling of lipid metabolism, protein palmitoylation, and metabolic disorder pathways. It should not be used in protocols requiring aqueous solubility or long-term storage of solutions, as stability and reproducibility depend on strict adherence to handling and reconstitution guidelines.

• Mitoxantrone HCl Disrupts ERα via DBD-LBD Interface Targetin

  2026-06-29

  This study uncovers a novel mechanism by which Mitoxantrone HCl, a DNA topoisomerase II inhibitor, disrupts estrogen receptor alpha (ERα) function by targeting its DBD-LBD interface, driving rapid proteasomal degradation. These findings offer a promising strategy to overcome resistance in hormone-driven breast cancer and broaden the research applications of Mitoxantrone beyond its canonical DNA damage activity.

• Cytochalasin D: Actin Polymerization Inhibitor for Cell Upta

  2026-06-29

  Cytochalasin D from APExBIO enables precise modulation of actin dynamics, unlocking new possibilities in cell uptake, oncology, and antiviral research. This guide translates cutting-edge findings into actionable protocols and troubleshooting strategies for reproducible results.

• Berberine Hydrochloride: New Horizons in Gut–Bone Axis Assay

  2026-06-28

  Explore how Berberine hydrochloride advances metabolic and osteoimmune research through unique modulation of the gut–bone axis. This article delivers in-depth scientific analysis and practical assay guidance for leveraging this potent bioactive alkaloid.

• Dextran Sulfate Sodium Salt: Powering IBD and Colitis Models

  2026-06-27

  Dextran sulfate sodium salt (MW 35000-45000) enables highly reproducible, translationally relevant models of intestinal inflammation. This guide delivers actionable protocol enhancements, troubleshooting strategies, and new insights from recent research, making it a must-read for teams refining their mouse model of inflammatory bowel disease workflows.

• NIR-Triggered Cobalt Single-Atom Enzymes for Multimodal Canc

  2026-06-26

  This study introduces a near-infrared (NIR)-activated cobalt single-atom enzyme system for synergistic photodynamic, photocatalytic, and photothermal therapy in head and neck cancer. By amplifying highly reactive oxygen species (hROS) and inducing mild hyperthermia, the approach achieves enhanced tumor ablation while preserving healthy tissue, representing a conceptual advance in noninvasive phototherapy.

• Magnetic Stimulation Modulates GABAA ε to Reverse Schizophre

  2026-06-26

  This study demonstrates that precise magnetic stimulation targeting the left prelimbic cortex downregulates the GABAA receptor ε subunit, significantly reversing schizophrenia-like behaviors and synaptic abnormalities in mouse models. The findings identify Gabre as a promising molecular target for neuromodulatory interventions in schizophrenia research.

445 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page